MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q3
hinzugefügt 07.11.2025
ALX Oncology Holdings Anteile 2011-2026 | ALXO
Anteile Jährlich ALX Oncology Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.2 M | 43 M | 40.7 M | 40.3 M | 18.5 M | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 52.2 M | 18.5 M | 38.9 M |
Anteile Vierteljährlich ALX Oncology Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.6 M | 53.4 M | 53.4 M | 53.1 M | 52.7 M | 51.8 M | 50.1 M | 50 M | 41.1 M | 40.9 M | 40.9 M | 40.9 M | 40.7 M | 40.7 M | 40.6 M | 40.6 M | 40.4 M | 40.2 M | 40.1 M | 39.8 M | 29.7 M | 3.16 M | 3.14 M | 3.17 M | 3.1 M | 3.09 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 53.6 M | 3.09 M | 36.5 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M |  USA |
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
128 M | $ 320.5 | 0.16 % | $ 40.9 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.21 B | - | -15.15 % | $ 60.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | USA |
 |
Amarin Corporation plc
AMRN
|
408 M | $ 15.23 | 3.25 % | $ 6.21 B |  Irlanda |
 |
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M |  Canada |
 |
I-Mab
IMAB
|
187 M | - | - | $ 866 M |  China |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
Aptorum Group Limited
APM
|
5.45 M | $ 0.84 | 2.78 % | $ 4.58 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
56.3 M | $ 2.94 | 10.11 % | $ 165 M | China |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M |  France |
 |
AlloVir
ALVR
|
5.01 M | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
2.41 B | $ 3.57 | - | $ 8.59 B |  Australia |
 |
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | USA |
 |
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | USA |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
60.3 M | - | - | $ 1.01 B | USA |
 |
Aptose Biosciences
APTO
|
699 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
54.8 M | $ 221.09 | -0.42 % | $ 5 B |  Danmark |
 |
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
244 M | $ 110.69 | 0.32 % | $ 27.2 B | Germany |
 |
Cabaletta Bio
CABA
|
1.17 M | $ 2.66 | 8.81 % | $ 3.11 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
60.8 M | - | -6.81 % | $ 3.04 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
18.8 M | - | 17.91 % | $ 11.1 M | USA |
 |
Burford Capital Limited
BUR
|
219 M | $ 9.19 | 2.4 % | $ 1.47 B | Britain |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
1.08 K | - | -10.17 % | $ 12.2 K | USA |
 |
Athira Pharma
ATHA
|
38.5 M | - | - | $ 269 M | USA |
 |
Athersys
ATHX
|
224 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.18 B | $ 4.54 | 6.07 % | $ 9.88 B |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
255 M | $ 1.46 | -0.34 % | $ 373 M | Britain |
 |
Amneal Pharmaceuticals
AMRX
|
309 M | $ 14.66 | 0.93 % | $ 4.53 B | USA |
 |
Codexis
CDXS
|
73.4 M | $ 1.28 | -0.88 % | $ 94 M | USA |
 |
AIkido Pharma
AIKI
|
6.18 M | - | 1.93 % | $ 17.4 M | USA |
 |
AVROBIO
AVRO
|
44.3 M | - | 1083.1 % | $ 745 M | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | USA |
 |
Compugen Ltd.
CGEN
|
89.5 M | $ 1.79 | 4.56 % | $ 160 M | Israel |